SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for…
- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive…
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant…
How Avio Health Is Rewiring Medicine for the Age of AI PALO ALTO, Calif. , July 15, 2025 /PRNewswire/ -- Today,…
July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)…
Company also announces new 500-patient SUMMIT RISE study at the Society of NeuroInterventional Surgery annual meetingSAN MATEO, Calif., July 14,…
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…
Study shows criminality is associated with damage to a key brain pathway involved in emotional control and judgment AURORA, Colo.,…
Science-backed tools help parents and children connect—improving emotional well-being and reducing behavior struggles NEW YORK, July 10, 2025 /PRNewswire/ --…
Positive Discussion on Path Forward for Registrational ProgramPURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company…